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Abstract
During the 2009 pandemic H1N1 (pH1N1) influenza outbreak, obese individuals were at greater
risk for morbidity and mortality to pandemic infection. However, the mechanisms contributing to
greater infection severity in obese individuals remain unclear. Although most individuals lacked
pre-existing, neutralizing antibody protection to the novel pH1N1 virus, heterologous defenses
conferred from exposure to circulating strains or vaccination have been shown to impart protection
against pH1N1 infection in humans and mice. Because obese humans and mice have impaired
memory T-cell and antibody responses following influenza vaccination or infection, we
investigated the impact of obesity on heterologous protection to pH1N1 infection using a mouse
model of diet-induced obesity. Lean and obese mice were infected with influenza A/PR/8/34 and
five weeks later challenged with a lethal dose of heterologous pH1N1 (A/Cal/04/09). Cross-
neutralizing antibody protection was absent in this model, but obese mice exhibited a significantly
lower level of non-neutralizing, cross-reactive pH1N1 nucleoprotein antibodies following the
primary PR/8 infection. Further, obese mice had elevated viral titers, greater lung inflammation,
lung damage, and an increased number of cytotoxic memory CD8+ T cells in the lung airways.
Although obese mice had more regulatory T cells (Tregs) in the lung airways compared with lean
controls during the pH1N1 challenge, Tregs isolated from obese mice were 40% less suppressive
than Tregs isolated from lean mice. Taken together, excessive inflammatory responses to pH1N1
infection, potentially due to greater viral burden and impaired Treg function, may be a novel
mechanism by which obesity contributes to greater pH1N1 severity.
Introduction
The novel 2009 pandemic H1N1 influenza A virus (pH1N1) is unique in several aspects.
Despite causing greater disease severity in animal models compared to seasonal H1N1
strains (1–4), the pH1N1 virus caused relatively mild, uncomplicated symptoms in humans
(5, 6). Further, in contrast to seasonal influenza epidemics, children and nonelderly adults
were disproportionately susceptible to pH1N1 infection compared with elderly individuals
(7, 8), with estimates that approximately 90% of pH1N1 deaths occurred in the nonelderly
population (9). Clinical and epidemiological data suggest the lower susceptibly in
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individuals over 65 y of age is likely due to the presence of cross-reactive anti-
hemagglutinin antibodies generated from previous exposure to pre-1950 influenza strains (8,
10–12). Because a majority of the population is naïve to these past circulating influenza
strains, and recently circulating (pre-2009) seasonal strains and influenza vaccines did not
elicit a robust cross-reactive antibody response, most individuals lacked neutralizing
antibody protection against pH1N1 infection (10, 12–15).
Although antibodies are important for the control and even prevention of influenza infection,
in their absence, influenza-specific T cells are essential in limiting influenza severity (16,
17). Several recent studies in animals and humans have demonstrated that previous exposure
to seasonal influenza strains or vaccination can induce cross-reactive memory T cells that
have the capacity to limit pH1N1 disease severity (15, 18–23). In mice, seasonal influenza
viruses and vaccines elicit a memory T-cell response that can prevent morbidity and
mortality to a lethal pH1N1 challenge (21, 24–27). Additionally, seasonal influenza A-
specific memory T cells from humans (naïve to pH1N1) are capable of recognizing pH1N1
epitopes and can directly lyse pH1N1-infected target cells (19). Therefore, the ability of
cross-protective memory T cells to control pH1N1 infection could explain the relatively
benign symptoms experienced by a majority of those infected (19, 28). However, cross-
reactive antibody protection to pH1N1 cannot be ignored. Non-neutralizing antibodies
recognizing conserved epitopes, such as anti-nucleoprotein (NP) antibodies, have been
shown to contribute heterologous protection to influenza infection, reducing viral titers and
infection severity in mice (29, 30). Additionally, a primary seasonal infection can lead to an
accelerated production of pH1N1 antibodies during a heterologous pH1N1 infection, which
may facilitate pH1N1 viral clearance (25, 30).
Another novel characteristic of the pH1N1 virus is that obesity, defined as a BMI ≥ 30kg/
m2, was considered to be an independent risk factor for increased morbidity and mortality
following infection (31–35). Obesity is a global public health concern, affecting more than
one-in-ten of the world’s adult population (36). It is well-established that obesity impacts
several aspects of the immune response and increases susceptibility for a variety of
pathogens, including influenza virus (37). Although recent investigations in mice and
humans have begun to elucidate potential mechanisms by which obesity impairs anti-viral
immunity to influenza infection, the specific factors contributing to the increased severity
observed in the obese population remain unclear (37). We have previously demonstrated that
obese mice and humans exhibit impaired memory CD8+ T-cell responsiveness to influenza
stimulation (38, 39). Further, obese mice display impaired responsiveness to influenza
vaccination (40), and obese humans are unable to maintain long-term influenza antibody
levels following vaccination (39). Therefore, given the protective nature of cross-reactive
antibody and T-cell responses, we hypothesized that obesity impaired heterologous
immunity induced by previous influenza exposure, resulting in greater pH1N1 infection
severity.
In this study, we utilized a model in which lean and obese mice were initially infected with a
sublethal dose of influenza A/PR/8/34 (H1N1, PR8). After 5 wk, mice were challenged with
a lethal dose of heterologous pandemic A/Cal/04/09 (H1N1, pH1N1). Similar to results
shown previously in lean, chow fed mice (21), we found that priming with PR8 effectively
prevented mortality from pH1N1 infection in both lean and obese mice in the absence of
cross-reactive neutralizing antibodies. However, obese mice exhibited a lower level of cross-
reactive pH1N1 nucleoprotein (NP) antibodies 5 wk after the PR8 infection, and a lower
proportion of obese mice generated pH1N1 HAI antibodies following the secondary
challenge. Consequently, obese mice had greater lung viral titers, more lung pathology as
well as an increased number of cytotoxic memory CD8+ T cells in lung airways during the
pH1N1 infection. Given the excessive inflammation, infiltration, lung damage and cytotoxic
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CD8+ T-cell responses in the lungs of obese mice during the lethal pH1N1 challenge, we
investigated the impact of obesity on regulatory T cells (Tregs) as a potential mechanism for
the inability to control the antiviral responses in the lung. Unexpectedly, obese mice had
nearly twice as many Tregs in the lung airways during the heterologous secondary pH1N1
infection compared with lean mice. However, ex vivo analysis of Treg function revealed that
Tregs isolated from obese mice were significantly less suppressive than those isolated from
lean mice. Therefore, an excessive inflammatory response in the lungs, potentially due to a
combination of elevated viral titers and impaired Treg function, may be a mechanism by
which obesity enhances pH1N1 infection severity.
Materials and methods
Mice and diets
Weanling, male, C57BL/6J mice were obtained from The Jackson Laboratory (Bar Harbor,
ME) and fed a low fat diet with 10% kcal fat (Research Diets D12450B) or high fat diet with
45% kcal fat (Research Diets D12451, New Brunswick, NJ). In addition to inducing weight
gain, high fat diets are considered to be pro-inflammatory (41). Mice were maintained on the
diets for 15–18 wk as described below. Mice were housed in isolation cubicles at the
University of North Carolina Animal Facility (fully accredited by the American Association
for Accreditation of Laboratory Animal Care). All experimental procedures involving mice
were approved by the UNC Institutional Animal Care and Use Committee.
Influenza virus and infection in mice
Influenza A/Puerto Rico/8/34 (H1N1, PR8), obtained from American Type Culture
Collection (Manassas, VA), was utilized for primary infections. Pandemic influenza A/
California/04/09 (H1N1, pH1N1) was obtained from BEI resources (Manassas, VA) and
was used for secondary infections. Both PR8 and pH1N1 were propagated in the allantoic
cavities of 10–12-day-old embryonated chicken eggs. At 72 h post-infection, allantoic fluid
from eggs was harvested and clarified by centrifugation at 5000 × rpm for 10 min at 4°C,
aliquoted and stored at −80°C. The stock viral titers of PR8 and pH1N1 were determined by
a modified 50% tissue culture infective dose (TCID50) in Madin-Darby canine kidney cells
using hemagglutination as an endpoint (42) and evaluated by the method of Reed and
Muench (43). For influenza inoculations, mice were lightly anesthetized by isoflurane
inhalation and inoculated via non-invasive oral aspiration (44, 45) with 0.05mL of viral
inoculum diluted in PBS. For re-challenge studies, mice were maintained on the designated
low fat or high fat diet for 15 wk and then infected with 11.4 TCID50 PR8 for a primary
infection. Mice were monitored and weighed daily for 14 days post-infection (dpi) following
the primary PR8 infection. Five weeks after the primary PR8 infection, a similar period of
time as performed by others (27, 30, 38, 46), mice were rechallenged with 5×103 TCID50
pH1N1, a previously determined lethal dose (approximately 10 LD50). Following the
secondary pH1N1 infection, mice were weighed daily. For isolation of Treg cells from
mouse splenocytes or harvesting of sera during the primary PR8 infection, mice were
maintained on a high fat or low fat diet for 18 wk.
Quantitation of viral titers
Viral titers in lung tissue were determined by a modified TCID50 using hemagglutination as
an endpoint as previously described (47). Briefly, the lung tissue from lavaged mice was
harvested and frozen in liquid nitrogen for subsequent processing. The supernatant from
each homogenized lung was collected, serially diluted and added to 80% confluent Madin-
Darby canine kidney cells in replicates of six in 96-well pates. TCID50 was determined
using the Reed and Muench method (43), and values were normalized to lung tissue weight
(38).
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Hemagglutination inhibition and microneutralization assays
Sera were collected from individual mice, at days 0 (five weeks after the primary PR8
infection, naïve to pH1N1), 5, 8 and 14 following the secondary pH1N1 challenge and
hemagglutination inhibition (HAI) titers were determined. Briefly, sera were treated with
receptor destroying enzyme (RDE; Denka Seiken, Tokyo, Japan) overnight, followed by
inactivation at 56°C for 1 h, and a final dilution to 1:10 with PBS. RDE-treated sera were
then incubated with either pH1N1, PR8 or influenza A/Victoria/361/2011 (negative control)
for 15 min at room temperature (primary PR8 infection sera was incubated with PR8 alone).
After a 1 h incubation at 4°C with either 0.5% turkey RBC (PR8, pH1N1) or 0.5% chicken
RBC (PR8, A/Victoria/361/2011), HAI titer was determined by the reciprocal of the highest
dilution of serum to completely inhibit hemagglutination. Positive and negative controls as
well as back titrations of virus were included on each individual plate.
Microneutralization assays were performed on sera from PR8-infected mice at 35 dpi as
previously described (48). Briefly, 100 TCID50 of either PR8 or CA/09 were added to two-
fold dilutions of RDE-treated sera, and serum-virus mixtures were incubated at 37°C, 5%
CO2 for 1 h. Following incubation, 3 × 105 MDCK cells were added to each well and plates
were incubated overnight at 37°C, 5% CO2. Plates where then fixed with 80% acetone,
blocked for 2 hours at room temperature and an ELISA was performed using mouse anti-
influenza A NP monoclonal antibody mixture (BEI Resources) followed by Peroxidase-
conjugated goat anti-mouse IgG (Jackson Immunoresearch, West Grove, PA). ELISA plates
were developed for 10 min using Substrate Reagent (R&D Systems, Minneapolis, MN),
stopped using a 2N H2SO4 solution and absorbance of each well was read at 450nm. Wells
were considered positive for microneutralization at an OD below or equal to 50% of the
MDCK cells being infected.
Influenza nucleoprotein ELISA
Anti-nucleoprotein antibodies in the sera of lean and obese mice 35 days after the primary
PR8 infection were measured by ELISA. Briefly, 8ug/mL of purified pH1N1 nucleoprotein
(A/California//06/2009, Immune Technology Corp., New York, NY) was coated on ELISA
plates (BD Falcon, San Jose, CA) overnight at 4°C in coating buffer. Influenza A/Cal/
04/2009 NP was not commercially available, so purified NP from the A/Cal/06/2009
pandemic strain was used. Subsequently, ELISA plates were blocked with 1% BSA for 1h at
37°C, washed and then incubated with mouse sera (1:400 dilution) overnight. Following the
overnight incubation, plates were washed and incubated with HRP-conjugated goat anti-
mouse IgG (Invitrogen, Carlsbad, CA) antibody (1:2000 dilution) for 1h at 37°C. After
washing, the assay was developed with the TMB Substrate Kit (Thermo Scientific,
Rockford, IL) per manufacturer’s instructions. Optical density was measured at 405nm, and
the optical density of uninfected control sera was subtracted from the 35 dpi experimental
samples.
Lung histopathology
At 5 dpi, the left lobe of the lung was harvested from lean and obese mice, inflated with 4%
paraformaldehyde and maintained in 4% paraformaldehyde for 48 h, after which samples
were transferred to 70% ethanol. Tissues were paraffin embedded, and three 5μm (separated
by 100μm) sections (per lung sample) were processed for H&E staining by the UNC Animal
Histopathology Core Facility. The extent of lung pathology was scored blindly according to
relative degree of mononuclear infiltrate on a scale from 0 to 4: 0, no inflammation; 1, mild
influx of inflammatory cells; 2, increased inflammation with ~25–50% of the total lung
involved; 3, severe inflammation involving 50–75% of the lung; and 4, almost all lung tissue
contains inflammatory infiltrate (38).
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Bronchoalveolar lavage total protein and albumin measurements
To recover bronchoalveolar lavage (BAL) fluid, the trachea of killed mice were exposed and
cannulated with a 22-guage angiocath, and the lungs were then lavaged with a series of 4
washes with unsupplemented HBSS, totaling 3.75mL (one 0.75mL and three 1mL washes).
BAL fluid supernatant was collected from the initial 0.75mL lavage and was subsequently
used for total protein, and albumin detection. The cells from the series of BAL washes for
each mouse were combined for subsequent flow cytometry analysis. BAL fluid was
harvested at 5, 8 and 14 days following the secondary pH1N1 infection. BAL supernatants
from 5 and 8 dpi were diluted 1:10, and total protein was measured (BCA kit, Sigma
Aldrich, St Louis, MO). BAL supernatants were diluted 15,000 fold prior to measuring
albumin levels per manufacturer instructions of the Mouse Albumin ELISA Kit (Genway
Biotech, Inc., San Diego, CA).
Quantitation of lung cytokine gene expression
Lung tissue samples were collected at day 0 (five weeks after the primary PR8 infection,
naïve to pH1N1) and 5, 8, and 14 days following the secondary pH1N1 infection. Total
RNA was isolated using the TRIzol method (Invitrogen), and reverse transcription was
performed with use of the Superscript II First Strand Synthesis kit (Invitrogen) using oligo
(dT) primers. Expression levels of cytokines and chemokines were quantified using qRT-
PCR as previously described (42).
Flow cytometry
Splenocytes and cells from draining mediastinal lymph nodes (mLN) were isolated as
previously described (38). For analysis of surface proteins of T-cell populations, single-cell
suspensions were simultaneously incubated with Fc blocker (anti-CD16/CD32) and stained
in PBS (with 1% FBS) with the following monoclonal antibodies: CD3 (APC/Cy7), CD62L
(Brilliant Violet 421) and CD8 (PerCP) from BioLegend (San Diego, CA); CD4 (FITC, PE-
Cy7), CD25 (PE-Cy7), CCR7 (APC), CD44 (PE-Cy7) and CD62L (E450) from eBioscience
(San Diego, CA). MHC class I tetrameric complexes (PE) specific for the H-2Db-restricted
epitope of the nucleoprotein (NP, DbNP366-74; ASNENMETM) of PR8 were used to identify
NP-specific T cells and the irrelevant LCMV tetramer DbGP33-41 (PE) was used as a
negative control (NIH Tetramer Core Facility, Atlanta, GA). For intracellular cytokine and
transcription factor staining, cells were fixed and permeabilized with the Foxp3/
Transcription Factor Staining Buffer Set (eBiosciences) per manufacturer’s instructions.
Subsequently, cells were stained with Foxp3 (APC, eBioscience) for identification of Tregs.
For detection of the intracellular cytokines IFN-γ (APC, eBioscience) and granzyme B
(GzB, FITC, eBioscience), 1–5×105 BAL cells were stimulated under the following
conditions for 6 h in the presence of Golgi Plug (BD Biosciences, San Jose, CA) per
manufacturer instructions: incubated with heat-inactivated pH1N1 (inactivated by a 1 h
incubation at 56°C) at a multiplicity of infection (MOI) of 1×10−3; incubated with heat-
inactivated pH1N1 (MOI=2×10−3) with antigen-presenting cells (splenocytes from lean
mice depleted of nonadherent cells) pulsed with heat-inactivated pH1N1 (MOI=0.1) at a
ratio of 1 APC:15 BAL cells; or 0.08μg/mL of Con A. Samples were analyzed on a CyAn
ADP Analyzer flow cytometer (Beckman Coulter, Inc., Fullerton, CA) and cytometry data
were analyzed with FlowJo software (TreeStar, Ashland, OR). T-cell populations were
analyzed by a doublet exclusion gate for all cells followed by gating of CD3+ T cells for
further analysis of CD4+ and CD8+ T-cell populations.
Suppression Assay
Treg suppression assays were performed similar to De Rosa et al. (49). Tregs were isolated
from pooled splenocytes of three naive lean or three naïve obese mice. CD4+CD25+ Tregs
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and CD4+CD25− T effector cells (Teff) were isolated using the Dynabeads FlowComp
Mouse CD4+CD25+ Treg Cells kit (Invitrogen) and stimulated with Dynabeads mouse anti-
CD3/28 (0.5 bead/Teff; 5×104 Teff per well). The Treg cells (≥95% Foxp3+ by FACS
analysis) and Teff cells (≤5% Foxp3+) were cocultured at a ratio of 1:2 in round-bottom 96-
well plates with complete RPMI medium. Only Teff cells from lean mice were used in the
assay to eliminate concern of a discrepancy in obese mouse Teff cell proliferation. Cells
were stimulated for 72 h, and cells were pulsed with [3H]thymidine (PerkinElmer, Boston,
MA) for the last 16 h of culture. Cells were harvested onto glass fiber filter paper (Brandel
Inc., Gaithersburg, MD), and radioactivity was measured using a Wallac 1409 liquid
scintillation counter (Wallac, Turku, Finland).
Statistical analysis
JMP Statistical Software (SAS Institute, Cary, NC) was used for all statistical analyses.
Statistical significance for parametric data was evaluated using the two-tailed unpaired
Student t test to compare dietary groups. For nonparametric data, the Wilcoxon signed rank
test was used. Lastly, for the percentage of mice with HAI titers at each dpi, the 2-tailed
Fisher’s exact test was used. Differences between means were considered significantly
different at p<0.05.
Results
Heterologous immune defenses prevent mortality from a lethal pH1N1 challenge in lean
and obese mice
To investigate the impact of obesity on heterologous immunity to a lethal pH1N1 infection,
we utilized a diet-induced obese mouse model. To induce obesity, weanling, male C57BL/6J
mice were fed a high fat (45% kcal from fat) diet or a low fat (10% kcal from fat) control
diet for 15 wk (Fig. 1A). The OpenSource Diets® are composed of purified constituents and
are matched in every aspect except for fat and carbohydrate content. Mice fed a high fat diet
rapidly gained more weight than control mice and after 15 wk on the diet weighed
approximately 33% more (Fig. 1B). Mice were maintained on the respective high fat or low
fat diet throughout the course of the experiment, including both primary and secondary
infections.
To test if obese mice had compromised heterologous defenses, lean and obese mice were
initially infected with a sublethal dose of PR8 virus after the 15 wk of dietary exposure (Fig.
1A). As expected, obese mice lost significantly more weight (5.10±0.40g) compared with
lean mice (3.54±0.31g) following the primary PR8 infection, but when normalized to pre-
infection body weight, there were no differences in percent weight loss between lean and
obese mice (Fig. 1C). PR8 infected mice were maintained on their respective diets for 5 wk
to allow the mice sufficient time to recover. After 5 wk, having regained weight equivalent
to initial weight status prior to the PR8 infection (data not shown), mice were infected with a
lethal dose of pH1N1 virus. One-hundred percent of naïve (unprimed) lean and obese mice
rapidly succumbed to the lethal pH1N1 infection at 6 dpi (Fig. 1D). However, of the mice
previously infected with PR8, 100% of lean mice and 95% of obese mice survived the
pH1N1 challenge. Contrary to the initial primary infection, both lean and obese mice began
to lose weight early at 2 dpi following the secondary pH1N1 infection, with obese mice
nearly losing twice as much weight as lean mice over the course of the infection. However,
once normalized to body weight, weight loss was not significantly different between the two
groups (Fig. 1E).
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Diet-induced obesity impairs primary and secondary influenza antibody responses
We assayed sera for HAI antibodies 5 wk following the primary PR8 infection in lean and
obese mice to confirm that the pH1N1 virus was heterologously distinct in our hands. We
did not detect HAI antibodies to pH1N1 in sera from lean or obese mice previously infected
with PR8 (Fig. 2A). Further, microneutralization assays confirmed that the PR8 infection did
not induce cross-neutralizing protection to pH1N1 virus (Fig. 2B). Similarly, Guo et al. did
not detect cross-neutralizing antibodies to pH1N1 in sera from PR8-infected mice (21).
Therefore, reflective of what happened in the human population during the pH1N1 outbreak,
PR8 infected mice lacked pH1N1cross-reactive neutralizing antibodies.
As expected, 5 wk after PR8 infection, lean mice displayed elevated HAI and
microneutralization titers to PR8 but not pH1N1 (Fig. 2A/B). Surprisingly, none of the
obese mice had detectable HAI antibodies to PR8, and obese mice had nearly a 4-fold lower
PR8 microneutralization titer. Although PR8 HAI antibodies are not critical modulators of
secondary infection outcome in this model, the striking deficiency in PR8 HAI antibodies
prompted us to measure PR8 antibody levels during the primary PR8 infection to determine
if the reduced antibody levels at 35 dpi were a result of decreased antibody generation. At 7
dpi following the primary PR8 infection, obese mice had a lower mean PR8 HAI titer and a
lower percentage of obese mice (p=0.06) exhibited detectable PR8 HAI antibodies (Fig. 2C/
D). However, by 9 dpi and through 14 dpi, obese mice had similar levels of HAI antibodies
compared with lean mice. Therefore, obese mice exhibited delayed antibody generation
during the primary infection but were able to compensate and eventually exhibited similar
levels to that of lean mice. However, by 35 dpi, obese mice did not have any detectable PR8
HAI antibodies (Fig. 2C/D), indicating that obesity also impairs antibody maintenance. Kim
et al. demonstrated that obese mice have impaired responsiveness to influenza vaccination,
but obesity-induced impairments in antibody responses following infection in mice have not
previously been shown (40). Interestingly, we have similarly demonstrated that obese
humans have an impaired ability to maintain long-term levels of influenza antibodies (39).
Because of the striking deficiency of PR8 HAI antibodies in the obese mice at 35 dpi, we
also assessed pH1N1 HAI antibody levels following the secondary challenge. Previous
studies in mice have demonstrated that a primary heterologous influenza infection can lead
to an accelerated production of pH1N1 neutralizing antibodies during a secondary pH1N1
infection (25, 30), which could potentially impact infection outcome. We did not detect HAI
antibodies at 5 dpi in lean or obese mice; however, 72.7% of lean mice had HAI antibodies
at 8 dpi. By 14 dpi, 100% of lean mice had HAI antibodies (Fig. 3A/B). In contrast to lean
mice, 41.7% of obese mice generated detectable serum HAI antibodies at 8 dpi, and only
50% of obese mice had pH1N1 HAI antibodies at 14 dpi (Fig. 3A/B). Therefore, obese mice
displayed altered antibody responses during both primary and secondary infections.
Although PR8 HAI antibodies offer negligible protection during the secondary infection, we
measured PR8 HAI antibodies to determine if the impairments in antibody production
during the secondary infection were specific to pH1N1 or a more global defect. The
differences between lean and obese mice were striking, as 75% (day 5), 72.7% (day 8) and
83.3% (day 14) of lean mice had detectable levels of HAI antibodies to PR8 during the
secondary pH1N1 infection compared with 8.3% (day 5), 16.7% (day 8) and 33.3% (day 14)
of obese mice (Fig. 3C/D). As a negative control for all HAI titers from sera obtained during
the secondary infection, influenza A/Victoria/361/2011 (H3N2) was assayed in addition to
pH1N1 and PR8. Taken together, obese mice exhibited delayed or impaired antibody
generation during primary and secondary influenza infections, respectively, and impaired
antibody maintenance (35 days following the primary PR8 infection).
Although, PR8 antibodies do not neutralize pH1N1 virus infectivity (see Figure 2B),
nucleoprotein (NP) specific antibodies generated during a heterologous primary influenza
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infection or through vaccination have been shown to control virus replication during
influenza infections (29, 50, 51). Therefore, we next assayed the level of anti-pH1N1 NP
antibodies in lean and obese mice at 35 dpi. Interestingly, we detected that obese mice had a
significantly lower level of serum anti-pH1N1 NP antibodies (Figure 3E). Because NP
antibodies can regulate viral burden (29), we next measured lung viral titers in lean and
obese mice to determine if lower anti-NP antibody levels potentially impacted influenza
viral titers during the secondary pH1N1 infection. At 5 dpi, obese mice had greater than a
10-fold higher mean virus titer (p=0.05) in the lungs compared with lean mice (Fig. 3F).
Although viral replication is controlled through several cell types and effector responses, it
is plausible that reduced NP antibody levels resulted in greater viral burden in the lungs of
obese mice.
Obese mice develop greater lung airway inflammation following a secondary heterologous
pH1N1 infection
Given that obese mice exhibited elevated viral titers at 5 dpi, we next assessed how greater
viral burden impacted lung inflammation and pathology. Enumeration of BAL cells
following the secondary infection revealed that obese mice had nearly twice as many cells in
the lung airways at 5 dpi (Fig. 4A). Conversely, in the draining mLN, lean mice had
approximately twice as many immune cells as obese mice at 5 dpi (Fig. 4B). Despite the
lack of differences in inflammatory cytokine expression (Table I), obese mice had elevated
lung pathology scores (Fig. 4C) and a greater level BAL fluid protein at 5 dpi (Figure 4D).
To determine if the elevated level of immune cell infiltration and inflammation in the lungs
resulted in damage to the integrity of the respiratory epithelium in obese mice, we assayed
albumin levels in the lung airways. Consistent with heightened infiltrate and pathology at 5
dpi, we detected greater levels of BAL albumin at 5 dpi in obese mice (Figure 4E).
Obese mice have a heightened memory CD8+ T-cell response in the lung airways following
a lethal secondary pH1N1 infection
The protective role of memory T cells during secondary heterologous influenza infections is
well established (52, 53). Further, several recent investigations have demonstrated that
exposure to seasonal influenza strains or vaccination can elicit memory T cells that are able
to recognize viral epitopes of pH1N1, conferring cross-protection (15, 25). Both CD4+ and
CD8+ memory T cells have been shown to be important in limiting disease severity in
several models of pH1N1 rechallenge studies (21, 25, 27).
To determine if obesity influenced the distribution and activation of cross-reactive T cells,
BAL cells from mice previously infected with PR8 5 wk earlier and then challenged with
pH1N1 were stimulated with heat-inactivated pH1N1 virus, pH1N1-pulsed APCs or the
polyclonal mitogen, Con A, at days 5, 8 and 14 following the secondary pH1N1 infection.
Figure 5A demonstrates that all three methods of stimulation induced a robust IFN-γ
response in cross-reactive CD4+ T cells at 5 dpi. As expected, the addition of influenza-
pulsed APCs in culture with BAL cells resulted in an elevated IFN-γ response compared
with BAL cells incubated with heat-inactivated virus alone. Obesity did not impair IFN-γ or
GzB production by memory CD4+ T cells in response to the stimuli (Fig. 5B/C). There were
no differences in CD4+ T-cell IFN-γ median fluorescence intensity (MFI) or GzB MFI (data
not shown).
Next, we investigated potential differences in CD4+ effector memory T cells between lean
and obese mice as we have previously demonstrated that obese mice have an impaired CD8+
effector memory T-cell response (38). Effector memory T cells were distinguished by lack
of expression of the cell adhesion molecule, CD62L, which is inherently absent or low on
effector memory T cells (54). Because we detected differences in viral titers and lung
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pathology at 5 dpi, we focused on effector memory T-cell populations specifically on this
day. However, we did not detect any differences in IFN-γ or GzB production of
CD4+CD62L− effector memory T cells between lean and obese mice (Fig. 5D/E). This
suggests, at least partially, that cross-reactive CD4+ T-cell cytotoxic responses are intact in
obese mice.
We also determined how obesity affected the cross-reactive CD8+ T-cell response under the
same conditions described for CD4+ T cells. Approximately, 4–5% of CD8+ T cells from
lean and obese mice produced IFN-γ following stimulation with influenza-pulsed APCs at 5
dpi (Fig. 6A). After day 5, the magnitude of the CD8+ T-cell response declined in both lean
and obese mice (Fig. 6B/C). Interestingly, obese mice had a strikingly elevated number of
CD8+IFN-γ+ and CD8+GzB+ T cells at 5 dpi (Fig. 6B/C). Further analysis of the CD8+
memory T-cell population revealed that obese mice had an elevated number of
CD8+CD62L−IFN-γ+ T cells and a significantly greater number of CD8+CD62L−GzB+
effector memory T cells at 5 dpi as well (Fig. 6D/E). There were no differences in CD8+
IFN-γ MFI or GzB MFI (data not shown).
We used whole virus in BAL cell stimulations, and thus we were assessing the total
polyclonal response of the CD4+ and CD8+ memory T-cell pool. Since we detected
significant differences in the number of GzB producing effector memory CD8+ T cells in
obese mice, we next examined GzB production by effector memory T cells specific for a
specified viral epitope. As NP from PR8 shares 91% similarity with the pH1N1 NP (30), we
used the influenza tetramer DbNP366-74, allowing for detection of T cells specific for the
PR8 NP366-74 epitope during the secondary pH1N1 infection. Figure 6F demonstrates that
obese mice had a greater number of NP336-74 specific T cells producing GzB following
stimulation. Further, obese mice had a significantly greater number of NP366-74 specific
CD8+CD62L− T cells, and a significantly greater proportion of these cells produced GzB
(Fig. 6G). The elevated cross-reactive CD8+ T-cell response could be attributed to the
greater viral burden detected in the lungs of obese mice at 5 dpi. It is likely that greater viral
load induced excessive recruitment of CD8+ T cells to the lungs, and perhaps the elevated
CD8+ T-cell response was required to control the excess viral burden in the absence of
proper antibody defenses.
Obese mice have a greater number of CD4+CD25+Foxp3+ Tregs in the lung airways at 5 dpi
Numerous factors could contribute to the increased lung inflammation, lung infiltration, lung
damage and memory CD8+ T-cell responses in obese mice. Enhanced inflammatory
responses in the lungs between 1–5 dpi or altered expression of lung trafficking molecules
on immune cells could result in the observed differences in infiltration in the lung at 5 dpi.
However, we did not detect any differences in the percentage of mLN CD8+ T cells
expressing the trafficking molecules CD44, CD62L and CCR7 at 5 dpi, nor did we find any
differences in mLN or lung chemokine expression at 0 or 5 dpi (mLN data not shown).
We observed greater infiltration, lung damage and heightened CD8+ T-cell responses in the
lungs of obese mice, and Tregs have been shown to regulate all of these parameters in other
respiratory infection models (55, 56). Further, obesity has been reported to result in a
deficiency of anti-inflammatory Tregs in metabolic tissues such as white adipose (57) and
the liver (58). We therefore proceeded to investigate this unique cell type in the secondary
infection model as a potential mechanism for increased inflammation in the obese mice.
Figure 7A represents the gating scheme used to distinguish Tregs and demonstrates the Treg
distribution in the lung airways and mLN in lean and obese mice at 5 dpi. Although,
CD25−Foxp3+ Tregs were present in the lung airways and mLN following the secondary
infection, the majority of Foxp3+ T cells were CD25+ (Fig. 7A). BAL Treg number peaked
at 5 dpi in obese mice and continually decreased in number, whereas lean mice had
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consistent numbers of BAL Tregs from 5 to 8 dpi with a similarly low level of Tregs by 14
dpi (Fig. 7B). Interestingly, obese mice had more than twice as many BAL Tregs at 5 dpi
and nearly half as many mLN Tregs (Fig. 7C) compared with lean mice. Consistent with two
recent publications investigating Tregs during a primary influenza infection (59, 60), the
mLN in lean and obese mice contained a greater number of Tregs than the BAL
compartment following infection (Fig. 7C). There is little known regarding memory Tregs
during influenza infection nor the distribution and function of Tregs during a secondary
influenza infection. One would expect a greater presence of suppressive Treg cells to result
in a dampening of the inflammatory and cytotoxic responses in the lungs of obese mice (61).
However, we observed the opposite, and therefore investigated the possibility that obese
mice have impaired Treg suppressive function.
Tregs isolated from obese mice are less suppressive than those from lean mice
To compare Treg activity from lean and obese mice, we used a well-established suppression
assay (49). Tregs isolated from splenocytes were cocultured in the presence of CD4+CD25−
Teff cells isolated from lean mice. Tregs from lean and obese mice were only cocultured
with Teff cells isolated from lean mice to eliminate any possibility of a discrepancy in Teff
proliferation between lean and obese mice. Figure 8A demonstrates that isolated Treg
populations were greater than 95% Foxp3+ from both dietary groups, and less than 5% of
Teff cells isolated from lean mice were Foxp3+, confirming pure populations of isolated
cells. Interestingly, after a 72 h anti-CD3/CD28 polyclonal stimulation, Tregs isolated from
obese mice were found to be significantly less suppressive (Fig. 8B). After normalizing to
lean Treg activity, Tregs isolated from obese mice were 41% less suppressive (Fig. 8C).
Therefore, diet-induced obesity dramatically impaired Treg suppressive activity. There are a
wide variety of mechanisms that could contribute to the impaired Treg function in obese
mice. The level of Foxp3 expression in Treg cells is important for suppressive activity as
experimental reduction in Foxp3 results in impaired Treg suppressive function (62, 63).
Thus, we assayed Foxp3 protein expression levels in Tregs from splenocytes of lean and
obese mice, but we did not detect differences in Foxp3 levels (Fig. 8D) suggesting that
impairment in Treg function is due to a mechanism unrelated to Foxp3 expression.
Discussion
Globally, greater than 1.4 billion adults are overweight, and approximately 500 million of
these individuals are obese (36). In 2009, obesity was reported to be an independent risk
factor for hospitalization and death following pH1N1 influenza infection (32–34). Given the
prevalence of obesity and the consistent threat of influenza epidemics and pandemics,
understanding how excess adiposity affects the immune response to influenza infection is
important in potentially developing therapies to limit morbidity and mortality in this at-risk
population.
During the 2009 pandemic, a majority of individuals (nonelderly) lacked pre-existing
neutralizing antibody protection to pH1N1 (10, 12–15). Therefore, a number of
investigations have focused on the protectiveness of heterologous immunity to pH1N1
infection, conferred from previous exposure to circulating influenza strains or vaccines (19,
27, 28). Human studies and mouse models have demonstrated that cross-reactive T cells and
cross-reactive non-neutralizing antibody defenses can limit viral load and protect from a
lethal heterologous influenza infection (10, 19, 21, 30). Additionally, prior heterologous
infection can accelerate pH1N1 antibody generation during a secondary pH1N1 infection,
thus providing an additional mechanism by which heterologous immunity can limit pH1N1
infection severity (25, 30). However, obese humans and mice have been shown to have
impaired memory T-cell and humoral responses following vaccination or infection (38–40,
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64). Thus, we developed a mouse model to investigate if obesity results in enhanced pH1N1
infection severity due to impairments in heterologous immune defenses.
In this study, obesity did not impair the overall ability of heterologous immunity to prevent
mortality from pH1N1 infection as 95% of PR8 primed obese mice survived the lethal
secondary heterologous infection, whereas none of the naïve, obese mice survived the
pH1N1 infection. However, heterologous cellular and humoral responses were significantly
altered by obesity, and obese mice displayed greater lung damage during the secondary
pH1N1 infection. Obese mice exhibited a significant delay or impairment in antibody
generation during both primary and secondary influenza infections. Further obese mice
displayed significantly lower levels of cross-reactive anti-pH1N1 NP antibodies following
the primary PR8 infection. Subsequent investigation of viral titers confirmed that obese mice
had a greater lung viral titer at 5 dpi, perhaps due to reduced levels of cross-reactive anti-NP
antibodies. Consistent with greater viral load, obese mice had an elevated number of
infiltrating cells into the lung airways, heightened lung pathology, and greater BAL total
protein and albumin levels. Analysis of cross-reactive T-cell responses demonstrated that
obesity led to a heightened CD8+ T-cell response in the lung airways, but obesity did not
impact cross-reactive CD4+ T-cell distribution during the secondary infection. These data
point towards a model in which reduced levels of anti-NP antibodies resulted in greater lung
viral burden, which subsequently induced greater immune cell infiltration, lung damage and
heightened CD8+ T-cell responses in obese mice. Lastly, we investigated the impact of
obesity on Treg distribution during the secondary infection model. We found that obese
mice had a greater number of BAL Tregs at 5 dpi, but ex vivo analysis revealed Tregs
isolated from obese mice were significantly less functional than Tregs from lean mice.
Therefore, perhaps obese individuals experienced greater pH1N1 infection severity due to a
combination of impaired pH1N1 heterologous antibody defenses and excessive antiviral
immune responses in the lungs, which could not be controlled properly due to dysfunctional
Tregs.
Despite a lack of neutralizing antibody protection, antibody defenses may still impart
protection to a lethal pH1N1 infection in our model. A protective role for cross-reactive non-
neutralizing antibodies during influenza infection has been well established (29, 30, 50, 51).
LaMere et al. demonstrated that intact antibody defenses (i.e. somatic hypermutation and
class-switch recombination) were required for proper heterologous immunity in the classical
X31 prime, PR8 challenge, heterologous infection model (29). Further, influenza NP
vaccination or passive transfer of NP immune serum can limit viral replication in the lungs
of PR8 infected mice (29). Therefore, non-neutralizing antibodies can impart antiviral
activity, although the exact mechanisms by which anti-NP antibodies function remain
unclear (29). Interestingly, NP was detected in the 2008/09 trivalent inactivated vaccine, and
some individuals demonstrated increased levels of anti-NP antibodies following vaccination
(51). Therefore, non-neutralizing NP antibody protection is clinically relevant as well. The
non-neutralizing influenza antibody repertoire can also include antibodies targeting other
internal viral proteins such as the matrix protein (M1) and nonstructural protein 1 (NS1) (29,
30). However, the protective role of antibodies specific to these proteins is less established
and likely less protective compared with anti-NP antibodies (29, 30).
Another mechanism by which heterologous immunity may protect against pH1N1 is through
the acceleration of homologous pH1N1 antibodies produced during a secondary pH1N1
challenge. A primary heterologous infection followed by a pH1N1 challenge has been
shown to result in significantly enhanced production of pH1N1 neutralizing antibodies (25),
split pH1N1 antibodies and anti-NP antibodies compared with naïve mice infected with
pH1N1 (30). It is likely that cross-reactive CD4+ T cells facilitate this accelerated
homologous pH1N1 antibody production (25). We did not detect pH1N1 HAI antibodies at
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the early time-point of 5 dpi, however, we found that a significantly lower proportion of
obese mice exhibited detectable pH1N1 HAI antibodies 14 days after the secondary
challenge. Therefore, it is unlikely that this aspect of heterologous immunity contributed to
the observed outcomes in lean and obese mice. Of particular note, we found that obese mice
displayed a delayed production and impaired maintenance of PR8 antibodies following the
primary, sublethal PR8 infection. Further, obese mice had significantly lower mean PR8
HAI titers during the secondary infection, and a lower proportion of obese mice had
detectable PR8 HAI antibodies at all of the time points assayed. Although PR8 HAI
antibodies did not mediate protection in this model per se, the dramatic impact of obesity on
influenza antibody responses has clear public health implications. Kim et al. demonstrated
that obesity impairs the antibody response to pH1N1 vaccination in mice (40), but it has not
been reported that obesity alters antibody responses during the context of an infection.
Excessive antiviral and inflammatory immune responses in the lung, contributing to severe
immunopathology, are known to be one of the primary causes of influenza-related morbidity
and mortality (65, 66). Further, fatal pH1N1 infection is associated with enhanced
inflammation with high numbers of CD8+GzB+ cytotoxic T cells and excess local
production of IFN-γ in the lung (66). We similarly detected greater inflammation, lung
pathology and a greater number of CD8+GzB+ cytotoxic T cells in the lungs of obese mice
infected with pH1N1. Although, only mild symptoms were experienced by a majority of
individuals infected, severe immunopathology may partly explain why certain at-risk
groups, such as obese humans, experienced a worse outcome to pH1N1 infection.
Obesity is characterized by a state of chronic inflammation, likely due, in part, to the
simultaneous deficiency of Tregs in metabolic tissues (57). Because obesity negatively
impacts Treg distribution, we hypothesized that obese mice would have fewer Tregs in their
lungs, offering a potential explanation for the greater lung infiltration, inflammation,
pathology, damage and the heightened memory CD8+ T-cell responses detected in the lung
airways at 5 dpi. Tregs have been shown to regulate all of these parameters in other
respiratory infection models (55, 56, 67). Contrary to our expectations, we found that obese
mice had nearly twice as many Tregs in the lung airways at 5 dpi compared with lean mice.
Subsequent investigation of Treg function revealed that Tregs isolated from obese mice
were 41% less suppressive than those isolated from lean mice. Therefore, impaired Treg
function may have contributed to the excessive antiviral responses observed in the lungs of
obese mice at 5 dpi. Although, we did not show impaired Treg suppressive function in vivo
during the infection, the suppression assay suggests that in vivo function may be impaired as
well.
Betts et al. demonstrated that a primary influenza infection results in a robust, antigen-
specific Treg response, and influenza infection-induced Tregs were able to suppress antigen-
specific CD4+ and CD8+ T-cell proliferation and cytokine production (60). Further, a recent
study by Brincks et al. reported that during secondary influenza infections, antigen-specific
memory Tregs exhibit accelerated accumulation in the lungs and mLN compared with
primary infection responses and control memory CD8+ T-cell proliferation in a MHC class
II dependent antigen-specific manner (68). Interestingly, depletion of memory Tregs
resulted in heightened CD8+ T-cell responses, pulmonary inflammation and lung cytokine
expression during a secondary influenza infection (68). It is possible that obesity-induced
alterations in memory Treg responses could have contributed to the aberrant inflammatory
responses observed in obese mice during the secondary pH1N1 infection.
We utilized a mouse model of diet-induced obesity and heterologous influenza infection in
attempt to mirror clinical and epidemiological evidence. We found lower levels of non-
neutralizing influenza NP antibodies, heightened cross-reactive CD8+ T-cell responses,
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greater viral titers and lung pathology, and impaired Treg function in obese mice. We
propose that impaired antibody protection resulted in greater viral burden, which
subsequently drove heightened inflammatory responses that were not properly controlled by
dysfunctional Tregs. This study and numerous others have demonstrated obesity negatively
impacts the immune response to influenza infection (38, 40, 42, 64, 69–71). Yet, the exact
cellular and molecular mechanisms by which excess adiposity contributes to altered antiviral
defenses remain unclear (37). It is possible that one global defect in all immune cells can
explain impaired functionality in the obese, but it is more likely that a complex combination
of altered signaling pathways and responses ultimately impairs immunity and results in
greater influenza susceptibility (37).
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A sublethal influenza A/PR/8/34 infection induces heterologous protection against a lethal
pH1N1 challenge in lean and diet-induced obese mice. A, Weanling, male C57BL/6J mice
were placed on a high fat or low fat, control diet for 15 wk. Lean and obese mice were
infected with a sublethal dose of influenza A/PR/8/34. Thirty-five days after the primary
infection, mice were challenged with a lethal dose of pH1N1 and samples were harvested at
day 0 (naïve to pH1N1), and 5, 8 and 14 dpi. B, Mice fed a high fat diet gain significantly
more weight than mice fed a low fat, control diet (n≥40 per group). After one week and
throughout dietary exposure, high fat diet fed mice weigh significantly more than low fat
diet fed mice. C, Fifteen weeks after mice were placed on the designated diets, mice were
inoculated with a sublethal dose of PR8, and weight loss was monitored daily. D, Five
weeks after the primary PR8 infection, PR8 primed (two cohorts of n=46) and naive mice
(n=3–4) were challenged with a lethal dose of pH1N1. The naïve mice rapidly succumbed to
the pH1N1 challenge, whereas primed mice did not. E, Secondary pH1N1 infection weight
loss. Diet-induced weight gain graphs and infection weight loss graphs represent means ±
SEM of at least two independent experiments. *p<0.05 compared with obese mice.
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Obese mice exhibit delayed antibody production and impaired antibody maintenance
following a sublethal PR8 infection. A and B, HAI (A) and microneutralization (B) titers of
sera from lean and obese mice 5 wk after a primary PR8 infection, demonstrating that PR8
does not elicit a cross-neutralizing pH1N1 antibody response (n=9–10). C and D, PR8 HAI
titer (C) and percentage of mice with detectable PR8 HAI antibodies (D) following a
sublethal PR8 infection (n=8–11). The limit of detection for HAI and microneutralization
titers is 10. Each data point represents an individual animal. Bars represent mean HAI ±
SEM or percentage of mice with detectable PR8 HAI. *p<0.05, **p<0.005, ***p<0.0005.
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Obese mice have lower levels of cross-reactive anti-pH1N1 nucleoprotein antibodies and
exhibit greater lung viral titers during a secondary pH1N1 infection. A and B, Serum pH1N1
HAI titer (A) and percentage of mice with detectable pH1N1 HAI antibodies (B) during a
secondary heterologous pH1N1 challenge, n=10–12. C and D, Serum PR8 HAI titer (C) and
percentage of mice with detectable PR8 HAI antibodies (D) during a secondary
heterologous pH1N1 challenge, n=10–12. The limit of detection for HAI titers is 10. E,
Obese mice have lower levels of serum cross-reactive anti-pH1N1 NP antibodies 5 wk after
a primary PR8 infection, n=9–10. F, Obese mice have a greater viral burden at 5 dpi during
the pH1N1 rechallenge (n=12). No virus was detected (N.D.) at 0 or 8 dpi, n=5–6 at 0 and 8
dpi. Each data point represents an individual animal. Bars represent percentage of mice with
detectable HAI antibody or mean viral titer ± SEM. *p<0.05, **p<0.005 compared with lean
mice.
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Obese mice exhibit a greater inflammatory and pathological response in the lungs following
a secondary heterologous pH1N1 challenge. A and B, Enumeration of BAL cells (A) and
mLN cells (B) at 5, 8 and 14 dpi following the secondary pH1N1 challenge, n=9–12. Each
data point represents an individual animal. C, Representative H&E stained lung histology
slides at 40x and 100x magnification and pathology score at 5 dpi, n=3–4. D, Total protein
in BAL fluid at 5 and 8 dpi, n=5–6. E, Albumin levels in BAL fluid at 5 and 8 dpi, n=5–6.
Bars represent mean ± SEM, *p<0.05, **p<0.005 compared with lean mice.
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Exposure to PR8 elicits a rapid and robust memory CD4+ T-cell response following pH1N1
infection in both lean and obese mice. BAL cells from mice challenged with a secondary
heterologous pH1N1 infection were stimulated for 6h with heat-inactivated pH1N1 (n=5–6),
pH1N1 pulsed APCs (n=4–6) or Con A (n=5–6). A, Representative flow cytometry gating
scheme at 5 dpi, including mean % (SEM). B and C, Number of IFN-γ (B) and GzB (C)
producing CD4+ T cells after stimulation with pH1N1 pulsed APCs, n=4–6. D and E,
Number of IFN-γ (D) and GzB (E) producing effector memory CD4+ T cells after
stimulation with pH1N1 pulsed APCs at 5 dpi, n=4–6. Each bar represents the mean ± SEM.
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Obese mice have enhanced cross-reactive CD8+ T-cell responses at 5 dpi after a secondary
heterologous pH1N1 challenge. A, BAL cells from mice challenged with a secondary
heterologous pH1N1 infection were stimulated as described in the legend to Figure 4. A,
Representative flow cytometry gating scheme at 5 dpi, including mean percentage (SEM),
n=4–6. B and C, Number of IFN-γ (B) and GzB (C) producing CD8+ T cells after
stimulation with pH1N1 pulsed APCs, n=4–6. D and E, Number of IFN-γ (D) and GzB (E)
producing effector memory CD8+ T cells after stimulation with pH1N1 pulsed APCs at 5
dpi, n=4–6. F, Enumeration of GzB producing, NP366-74 specific CD8+ T cells in the BAL
compartment, n=4–6. G, Comparison of GzB production by NP-specific effector memory
CD8+ T cells stimulated with APCs at 5 dpi, n=4–6. Each bar represents the mean ± SEM,
*p<0.05 compared with lean mice at 5 dpi.
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Obese mice have a greater number of Tregs in the lung airways during a heterologous
secondary pH1N1 challenge. A, Representative BAL (n=5–6) and mLN (n=10–12)
CD4+CD25+Foxp3+ Treg gating scheme at 5 dpi, including mean percentage (SEM). B and
C, Enumeration of Tregs in BAL fluid (B) and mLN (C). Each bar represents the mean ±
SEM, and *p<0.05 compared with lean mice at 5 dpi.
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Tregs isolated from obese mice are significantly less suppressive than Tregs isolated from
lean mice. Pooled CD4+CD25− Teff cells and CD4+CD25+ Tregs were isolated from
splenocytes of naïve lean (n=3) and obese mice (n=3). A, Greater than 95% of isolated
Tregs expressed Foxp3 from lean and obese mice, and less than 5% of Teff cells expressed
Foxp3 as determined by FACS analysis, confirming pure populations of cells. B,
Suppression assay comparing functionality of lean Tregs and obese Tregs cocultured with
lean Teff cells at a ratio of 1:2 in the presence of anti-CD3/CD28 for 72 h. C, Normalized
suppressive activity of isolated Tregs. D, Foxp3 median fluorescence intensity (MFI) of
Tregs from splenocytes of lean and obese mice. Each data point represents an individual
animal, n=5–6. Each bar represents the mean ± SEM, and *p<0.05 compared with lean
mice.
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